Latest From Biotech Now

FOIA Attacks Against Biotech Scientists Get Personal

Alison Van Eenennaam

Much has been written and discussed online about the relationships between independent researchers and industry groups.  New York Times reporter Eric Lipton wrote about this in a detailed September 5 article, “Food Industry Enlisted Academics in GMO Lobbying War, Emails Show”. Lipton’s article comes about 6 months after U.S. Right to Know (USRTK) filed FOIA requests for emails and documents of more than forty public university faculty and staff members seeking to link these individuals Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , ,

Reality Check for AHIP: Competition Driving Down Costs for Hepatitis C Meds

lab_tech

Yesterday at a House Judiciary Committee hearing on competition in the healthcare marketplace, AHIP Executive Vice President Daniel Durham took the occasion to bemoan what he termed “monopoly pricing” in the pharmaceutical industry. He proceeded to cite the cost of two new specialty medicines for Hepatitis C, Gilead Sciences’ Sovaldi and Harvoni, as a “case study” of that problematic monopoly pricing. Durham’s analysis suffers from a particularly egregious flaw: Gilead and its products do not enjoy Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

Here are the Facts about the IPR Kill Rate

US_Patent_And_Trademark_Office

FiercePhrma recently ran an article repeating a dubious analysis of the crisis caused by the rapidly increasing number of biopharma related inter partes reviews (IPR) currently within the United States Patent and Trademark Office (PTO). It is troubling that in a single breath Ronny Gal both dismissed the biopharmaceutical industry’s concerns with the PTO’s IPR process and acknowledged that limited data prevents any firm conclusions about the potential impact of IPR on biotech innovation. If Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BIO Statement: Institute for Clinical and Economic Review Framework

medicine

This week, the Institute for Clinical and Economic Review (ICER) released its Value Assessment Framework. While we welcome a robust discussion on the value of treatments and cures, we have concerns with ICER’s methodology, which has not been validated, and preliminary conclusions which underestimate the value of innovative new medicines. We believe that the most important priority is to empower patients with information that will be helpful in clinical decision-making with their healthcare providers, and Read More >

Health  |  Leave a comment  |  Email This Post
Tags:

Health Affairs Study: Want to save money in Medicaid? Increase adherence.

Health Affairs

At BIO, we have long argued that the use of prescription medicines can yield substantial savings to other areas of the healthcare system by reducing costly hospitalizations, surgeries, visits to the emergency room and other non-drug drivers of health spending. A study published in Health Affairs this week further bolstered that point and quantified the potential savings that Medicaid could realize from better prescription drug adherence among beneficiaries. The authors found that increasing the number Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,